Skip to main content
SRPT
NASDAQ Life Sciences

Sarepta Lifts 2026 Revenue Guidance Floor by $50M as ELEVIDYS Slides

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$17.933
Mkt Cap
$1.856B
52W Low
$14.68
52W High
$24.68
52W Position info
22% above low
Off High info
27% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRPT sits 22% above its 52-week low of $14.68.

Summary

Sarepta posted Q3 2026 revenue of $381.4 million, down 5%, as ELEVIDYS US sales fell 37% to $83.5 million. It raised the low end of 2026 product revenue guidance by $50.0 million and trimmed the high end of expense guidance by $25.0 million. DM1 and FSHD multiple ascending dose data is expected in Q4 2026.


Key Events · Earnings and Guidance · SRPT

  • Q3 Revenue Falls 5% to $381.4M

    Total revenues were $381.4 million versus $399.4 million a year earlier. ELEVIDYS US net product revenue dropped 37% to $83.5 million under the ambulatory-only label, while PMO net product revenue of about $240.3 million offset the decline.

  • Guidance Raised at the Low End

    Sarepta raised the low end of full-year total net product revenue guidance by $50.0 million to a $1.25 billion to $1.3 billion range. It also lowered the high end of combined non-GAAP R&D and SG&A expense guidance by $25.0 million to $800-825 million.

  • Non-GAAP Profit and Positive Cash Flow

    Q3 2026 non-GAAP operating income was $22.9 million versus a $35.7 million loss a year ago. The company ended the quarter with $998.7 million in cash, cash equivalents, restricted cash and investments.

  • $62M Catalent Take-or-Pay Charge

    GAAP net loss was $28.5 million (-$0.27 per share). Cost of sales of $188.5 million included a $62.0 million take-or-pay charge for Catalent inventories Sarepta elected not to manufacture.


Analysis · SRPT · Life Sciences

The quarter tells two stories at once. ELEVIDYS US sales fell 37% to $83.5 million under the narrowed ambulatory-only label, yet the PMO franchise carried the period at roughly $240.3 million. Management raised the low end of full-year product revenue guidance by $50.0 million to $1.25-1.3 billion and cut the high end of expense guidance by $25.0 million. Sarepta also swung to non-GAAP operating income of $22.9 million and positive cash flow, ending with $998.7 million in cash, which funds the DM1 and FSHD programs. Those programs are the real swing factor: multiple ascending dose data for SRP-1003 and SRP-1001 is expected in Q4 2026, and Sarepta says it is already preparing Phase 3 manufacturing. A $28.5 million GAAP net loss (-$0.27 per share) includes a $62.0 million Catalent take-or-pay charge for inventory it elected not to manufacture.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRPT was trading at $17.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.68 to $24.68. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.65
Real-time Price: $13.60 info
Change: -$3.05 (-18%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.57
Real-time Price: $13.60 info
Change: -$3.97 (-23%) info
Market Cap: $1.429B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.60 info
Change: -$5.04 (-27%) info
Market Cap: $1.429B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.60 info
Change: -$5.43 (-29%) info
Market Cap: $1.429B info
SRPT
Jul 27, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.35
Real-time Price: $13.60 info
Change: -$2.75 (-17%) info
Market Cap: $1.429B info